(Q31061631)

PubMed publication ID

16985831

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985831%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1550785&resulttype=core&format=json

7 May 2020

1 reference

Sibylle Marihart

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1550785&resulttype=core&format=json

7 May 2020

Mike Harik

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1550785&resulttype=core&format=json

7 May 2020

Bob Djavan

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1550785&resulttype=core&format=json

7 May 2020

publication date

1 January 2005

1 reference

PubMed publication ID

16985831

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985831%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1550785&resulttype=core&format=json

7 May 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1550785&resulttype=core&format=json

7 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1550785&resulttype=core&format=json

7 May 2020

page(s)

203-210

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1550785&resulttype=core&format=json

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

7 May 2020

cites work

1 reference

12 December 2020

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer

1 reference

12 December 2020

Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men.

1 reference

12 December 2020

Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction

1 reference

12 December 2020

Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression

1 reference

12 December 2020

Characterization of 5alpha-reductase gene expression in stroma and epithelium of human prostate

1 reference

12 December 2020

Kinetic parameters of 5 alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates.

1 reference

12 December 2020

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

12 December 2020

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

1 reference

12 December 2020

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia

1 reference

12 December 2020

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor

1 reference

12 December 2020

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia

1 reference

12 December 2020

The influence of finasteride on the development of prostate cancer

1 reference

12 December 2020

Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia

1 reference

12 December 2020

Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor Dutasteride

1 reference

12 December 2020

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

12 December 2020

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

12 December 2020

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia

1 reference

12 December 2020

5α-Reductase Type 1 Immunostaining is Enhanced in Some Prostate Cancers Compared With Benign Prostatic Hyperplasia Epithelium

1 reference

12 December 2020

The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications

1 reference

12 December 2020

Cancer statistics, 2001

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1550785&resulttype=core&format=json

7 May 2020

PubMed publication ID

16985831

1 reference